are excited to present the inaugural Mental Healthcare Innovations Summit to discuss cutting edge innovations in:

Precision mental health

Awareness interventions

Digital mental health

Psychedelics

Inaugural Summit 

The Summit will raise awareness of cutting-edge mental health therapies and modalities and explore the policy levers and blockers that must be addressed to scale them.

We will investigate key questions such as the ethical responsibilities around designing health tech and scaling psychedelic-assisted therapy and awareness interventions. Lastly, participants will form partnerships with thinkers at the top of their fields which they can leverage to help change the face of mental healthcare.

Attendance

This 100-person summit will be open to those who play an active role in converting novel breakthroughs in mental healthcare into policy and practice to transform clinical mental healthcare.

Join our wait-list to get the latest event updates:

*In-person attendance is invite-only. Select portions will be livestreamed via Eventbrite. Stay tuned for the link.*

Who will be there?

Byron Katie

Byron Katie

Byron Katie is an American speaker and author who teaches a method of self-inquiry known as “The Work of Byron Katie.” She is the founder of Byron Katie International, an organization that includes the School for the Work and Turnaround House in Ojai, California. Time magazine describes her as “a spiritual innovator for the 21st century.”

Nichol Bradford

Nichol Bradford

Nichol Bradford is fascinated by human potential and technology. She is the CEO & Founder of the Willow Group and the Executive Director and co-founder of the Transformative Technology Lab, Conference, and TT200 List. Prior to becoming a leader in Transformative Technology, Bradford was a senior executive in video games with responsibility for strategy, operations and marketing for major brands that include: Activision Blizzard, Disney, and Vivendi Games — including operating World of Warcraft China.

Michael Snyder

Michael Snyder, PhD

Michael Snyder, PhD, is an American genomicist, systems biologist, inventor and entrepreneur. He is the Stanford B. Ascherman Professor and as of 2009, Chair of Genetics and Director of Genomics and Personalized Medicine at Stanford University School of Medicine and the former Director of the Yale Center for Genomics and Proteomics. During his tenure as chair at Stanford, the U.S. News & World Report has ranked Stanford University first or tied for first in Genetics, Genomics and Bioinformatics under his leadership. He is also the founder of 8+ biotech companies including QBio, JanuaryAI, Affometrix, and Personalis.

Dr. Jiyoti Mishra

Jyoti Mishra, PhD

Dr. Mishra is trained in the computational, cognitive and translational neurosciences. She is the founder of the Neural Engineering & Translation Labs (NEATLabs) at UCSD. Her lab innovates digital technologies for scalable brain health mapping, monitoring and precision therapeutics. Dr. Mishra’s interdisciplinary research interests are at the intersection of neuroscience and digital engineering, integrating machine learning methods to personalize and inform mental healthcare, education, and climate change adaptation efforts.

Daniel Kraft

Daniel Kraft, MD

Daniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, entrepreneur, and innovator and is serving as the Chair of the XPRIZE Pandemic &Health Alliance Task Force. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as faculty chair for Medicine at Singularity University since its inception in 2008, and is founder and chair of Exponential Medicine. 6x TedX and TEDMED speaker. Voted Digital Health Top 50.

Leanne Williams

Leanne Williams, MD

Dr. Williams is the founding Director of the Stanford Center for Precision Mental Health and Wellness. The Center connects researchers across the campus to advance high definition imaging biotypes for mental health, sensor technology, machine learning approaches, targeted therapeutics and the world’s first biotype-guided trials.

Within her Center, Dr. Williams’ leads the PanLab for Precision Psychiatry and Translational Neuroscience. The PanLab has developed a radical new way to understand and treat mental health disorders based on a personalized approach to neuroscience. Dr. Williams also leads department-wide initiatives in precision mental health as Associate Chair of Translational Neuroscience. She has a joint position at the Palo Alto VA Mental Illness Research, Education and Clinical Center where she is Director of Education and Precision Medicine.

Ruth O’Hara, PhD

Ruth O’Hara, PhD

Ruth O’Hara, PhD, is the Lowell W. and Josephine Q. Berry Professor at Stanford and is the Director of Stanford Center for Clinical and Translational Research and Education (SPECTRUM), as well as the Senior Associate dean of Research at the Stanford School of Medicine. In 2021, she was elected as Chair of the Faculty Senate.

James R. Doty, MD

James R. Doty, MD

James R. Doty M.D. is a compassion researcher, entrepreneur, pediatric neurosurgeon, neuroscientist, and philanthropist. He is the founding director of the Stanford Center for Compassion and Altruism Research and Education, and former CEO of Accuray (NASDAQ:ARAY). Dr. Doty is a New York Times bestselling author of Into the Magic Shop: A Neurosurgeon’s Quest to Discovery the Mysteries of the Brain and the Secrets of the Heart, and the founder of HappiAI, a data-driven tech startup that uses artificial intelligence and neuroscience to generate a personalized virtual friend to help people with anxiety & depression.

Ariel Ganz

Ariel Ganz, PhD

Ariel B. Ganz, PhD is a postdoctoral fellow at Stanford University in the Snyder Lab. Her research gives an academic lens to popular wellness practices to reveal clinically promising effective strategies for depression and well-being. She is a founding partner at Arben Ventures, investing in early-stage companies with global impact.

Ben Rolnik

Ben Rolnik

After a career in talent management & tech innovation, Ben realized that his true passion lies in Salutogenic Medicine —the medicine of health and thriving. As the Director of Stanford’s Healthcare Innovation Lab, Ben has a mission to fix the broken healthcare system. He is leading an effort with Stanford scientists to bridge the gap between technology and medicine. Their goal is to transition the world from healthcare 1.5 to healthcare 2.0 by providing breakthrough innovations that make personalized, precision healthcare an affordable reality for all people across the globe. He is also a founding partner at Arben Ventures.

Dr-Watts

Rosalind Watts, PhD

Dr Rosalind Watts is a clinical psychologist and the founder of ACER Integration. Her contributions to the field of psychedelic therapy are numerous and include the development of the the ACE model ‘Accept, Connect, Embody’, which has been used in clinical trials of both psilocybin and DMT, as well as the Watts Connectedness Scale, which is a psychometric tool for measuring outcomes of psychedelic therapy. Dr Watts is the former clinical lead on the Psilocybin for Depression trial at Imperial College London, the clinical track lead on the Synthesis Institute’s psychedelic practitioner training, and sits on the clinical advisory board of the Usona Institute.

Yuriy Blokhin

Yuriy Blokhin

Yuriy Blokhin is Founder and CEO at Homecoming, a digital integration platform for clinicians and therapists to use with their patients. Yuri was the first employee at the Canadian tech company Kik, where he helped create and design a cognitive therapy chatbot for teens. Additionally, Yuri is a founding member of the Heroic Hearts Project, a non-profit organization that connects traumatized veterans with psychedelic therapy.

Antoun Nabhan, JD

Antoun Nabhan, JD, is a biotech and medical device investor and executive. He is former VP of Pear Therapeutics, CFO of Establishment Labs, and VP of Corporate Development at Sagamore Bioventures.

Berra Yazar-Klosinski

Berra Yazar-Klosinski, PhD

Dr. Yazar-Klosinski, PhD, is Chief Scientific Officer of the MAPS Public Benefit Corporation (MAPS PBC). Dr. Yazar-Klosinski is responsible for development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.
Jon-David

Jon David

Jon David is Akili’s Chief Product Officer. He previously was Vice President and General Manager at Glu Mobile, acquired in 2021 by Electronic Arts, where he led the development of both new IP and hit franchises including Covet Fashion and Diner Dash Adventures. David also founded and served as CEO of Taunt, a technology-based fan engagement company focused on reinventing the way viewers engage with esports. Prior to Taunt, David spent more than 10 years at PopCap Games, which was acquired by Electronic Arts in 2011. He led development of games including Bejeweled Blitz, Plants vs. Zombies 2 and Plants vs. Zombies Garden Warfare.
Lauren-Packard

Lauren Packard, JD

Lauren works at the Tony Blair Institute for Global Change, where she focuses on science and innovation policy. Previously, she worked as a climate change litigator at the Center for Biological Diversity and for the California Department of Justice. She also serves on the board of the Robert Packard Center for ALS Research at Johns Hopkins.

Benedict-Macon-Cooney

Benedict Macon-Cooney

As Deputy Executive Director, Technology and Public Policy at the Tony Blair Institute for Global Change, Benedict works on accelerating science and innovation, with a particular focus on biotech, climate tech and the future of food. He started his career as an economist in Her Majesty’s Treasury, later becoming a speechwriter in the ministry. He has also worked in the Office of the President in Rwanda and on development issues in other countries.
Jess-Northend

Jess Northend

Jess is based at the Tony Blair Institute for Global Change, where she supports leaders in understanding and responding to the next generation of emerging technologies. She previously worked with some of the UK’s leading businesses and Her Majesty’s Government to improve productivity across the UK economy. She has served as a fellow at Harvard University’s Project on Workforce, and has been part of international teaching teams for leadership, ethics, and negotiation.

Terah-Collins

Terah Collins

Terah Collins is responsible for the product strategy and execution of multiomics at Oracle. She believes that genomic medicine must be enabled, accessible and consumable to provide the very best care for patients. She has spent over fifteen years in the industry working to incorporate genomics into medicine and enable clinicians to make the best decisions for patients at the point of care.
Becker_Jeffrey

Jeffrey Becker, MD

Jeffrey Becker, MD, trained at UCLA/NPI in both Medicine and Psychiatry with a focus on Neuropsychiatry and Functional Medicine. He is board-certified by the American Board of Psychiatry and Neurology as well as the American Board for Integrative and Holistic Medicine. He maintains clinical offices in Santa Barbara and Westwood and is affiliated with UCLA/NPI as Volunteer Clinical Faculty. He is a leading expert on Ketamine Therapy and is the Founder and CSO of Bexson Biomedical.

Designing the future
of mental healthcare

Get in touch, or join our waitlist.